Treximet patents expiration

TREXIMET Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7332183 CURRAX Multilayer dosage forms containing NSAIDs and triptans
Oct, 2025

(1 year, 11 months from now)



CURRAX Multilayer dosage forms containing NSAIDs and triptans
Apr, 2026

(2 years from now)

Treximet is owned by Currax.

Treximet contains Naproxen Sodium; Sumatriptan Succinate.

Treximet has a total of 2 drug patents out of which 0 drug patents have expired.

Treximet was authorised for market use on 15 April, 2008.

Treximet is available in tablet;oral dosage forms.

Treximet can be used as treatment of migraine; acute treatment of migraine.

The generics of Treximet are possible to be released after 02 April, 2026.

Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 15 April, 2008

Treatment: Treatment of migraine; Acute treatment of migraine


How can I launch a generic of TREXIMET before it's drug patent expiration?
More Information on Dosage

TREXIMET family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic